Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
The much-heralded Gilead and Galapagos partnership takes a big knock as the US biotech cuts some of its losses with the doomed arthritis project.
Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
With Gilead's big sellers forecast to drift, investors turn to its newer projects but find little comfort.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.